Application No. 10/565,007 Docket No.: 3493-0158PUS1

## AMENDMENTS TO THE CLAIMS

1.-11. (Cancelled)

12. (Currently Amended) A method Method for the treatment of alopecia or [[of]] hairloss comprising the administration to a patient in need thereof of a composition comprising:

a therapeutically effective amount of a peptide conjugate which is not coupled with zinc and which corresponds to general formula (II)

wherein

A represents the radical corresponding to

- a monocarboxylic acid of general formula (III)

R represents a linear or branched C<sub>1</sub>-C<sub>24</sub> aliphatic radical optionally substituted with a hydroxyl group, possibly containing one or more unsaturations,

Lipoic acid or its reduced form, dihydrolipoic acid, N-lipoyl-lysine or retinoic acid,

X represents a bend or 1 to 3 Lys residues, that are optionally methylated, or a bond, and Y represents an -OH or-NH<sub>2</sub> group, the amino acids being in D, L or DL form in the form of enantiomers or of diastereoisomers, and also the mixtures thereof, including recemic mixtures.

13. (Previously Presented) The method as claimed in claim 12, wherein the acid of general formula (III) is an omega-3 acid selected from the group consisting of α-linolenic acid, cervonic acid, timnodonic acid and pinolenic acid or a C<sub>1</sub>-C<sub>24</sub> aliphatic radical selected from the group consisting of acetic acid, myristic acid, palmitic acid, and hydroxydecenoic and decenoic acids, or an acid selected from the group consisting of lipoic acid or its reduced form, dihydrolipoic acid, N-lipoyl-lysine and retinoic acid.

Application No. 10/565,007 Docket No.: 3493-0158PUS1

14. (Previously Presented) The method as claimed in claim 13, wherein A is lipoic acid or acetic acid.

15. (Currently Amended) The method as claimed in claim 12, wherein the peptide conjugate of formula II is selected from the group consisting of the peptide conjugates of the following formula:

```
A-MeLys-Lys-Gly-His-Lys-NH2 (SEQ ID No. 5),
1-
2-
      A-MeLvs-Lvs-Glv-His-Lvs-NH2
                                       (SEO ID No. 6).
3-
      A-MeLys-Gly-His-Lys-NH2
                                      (SEQ ID No. 7),
      A-MeLys-Lys-Gly-His-Lys-OH (SEQ-ID No. 8),
4-
5-
      A-MeLys-Lys-Gly-His-Lys-OH
                                       (SEQ ID No. 9),
6-
      A-MeLvs-Glv-His-Lvs-OH
                                     (SEQ ID No. [[11]] 10),
7- A-Lys-Lys-Gly-His-Lys-NH<sub>2</sub> (SEO ID No. 11).
8-
      A-Lys-Gly-His-Lys-NH2
                                     (SEQ ID No. 12),
9-
      A-Lvs-Lvs-Glv-His-Lvs-OH
                                  (SEO ID No. 13), and
10-
      A-Lys-Gly-His-Lys-OH
                                      (SEO ID No. 14),
```

A being an acid of general formula (III) as defined in claim 12.

16. (Previously Presented) The method as claimed in claim 12, wherein the peptide conjugate of formula II is chosen from:

```
Lipoyl-Lys-Gly-His-Lys-NH<sub>2</sub>(SEQ ID NO:12), or
Ac-Lys-Gly-His-Lys-NH<sub>2</sub> (SEQ ID NO:12)
```

Application No. 10/565,007 Docket No.: 3493-0158PUS1

17. (Previously Presented) The method as claimed in claim 12, wherein said composition further comprises a compound that improves hair regrowth, selected from the group consisting of minoxidil, nicotinic acid esters, anti-inflammatory agents, retinoic acid or derivatives thereof, retinol and 5α-reductase inhibitors.

## 18. (Cancelled)

19. (Previously Presented) The method as claimed in claim 12, wherein the administration is made by topical route and wherein said composition further comprises a UVB-screening agent selected from the group consisting of p-aminobenzoic acid (PABA) and esters thereof, cinnamates, salicylates, benzimidazoles, benzylidenecamphor derivatives, and triazines.

## 20. - 22. (Cancelled)

- 23. (Previously Presented) The method as claimed in claim 12, wherein the administration is an application to the scalp of the patient.
- 24. (Previously Presented) The method as claimed in claim 12, wherein the peptide conjugate of formula (II) is present at a concentration of between 10<sup>-8</sup> and 10<sup>-3</sup> M of the total concentration.